JMKX 000197
Alternative Names: JMKX-000197Latest Information Update: 28 Jul 2026
At a glance
- Originator Jemincare
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Malignant pleural effusion
- Preclinical Bladder cancer
- No development reported Head and neck cancer
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for research development in Head-and-neck-cancer in China
- 28 Jun 2026 No recent reports of development identified for phase-I development in Malignant-pleural-effusion in China (Intrapleural, Injection)
- 14 Jun 2026 Shanghai Jeyou Pharmaceutical plans a phase II trial for Malignant pleural effusion in China (Intrapleural, Injection) in August 2026 (NCT07649369)